Pentixapharm Holding AG Advances with FDA Approval and Capital Increase Plan

Pentixapharm Holding AG has received the FDA's green light for its Phase 3 PANDA study, set to start later this year. The study aims to evaluate a novel imaging approach for patients with primary aldosteronism, seeking to enhance current diagnostic procedures. The study will involve around 270 patients in the US, with patient enrollment expected by the end of 2026.

The company plans a capital increase, offering up to 10 million new shares. The proceeds will fund the PANDA study and further US market expansion. Major shareholder Eckert Wagniskapital intends to fully participate in the subscription rights offering.

Moreover, Pentixapharm is undergoing a financial review by BaFin concerning their 2024 financial statements. BaFin noted potential overstatement issues; however, Pentixapharm believes these do not materially affect operations or liquidity. The company plans to respond accordingly to BaFin's draft decision.